In the last trading session, 7.11 million Gilead Sciences, Inc (NASDAQ:GILD) shares changed hands as the company’s beta touched 0.31. With the company’s per share price at $110.09 changed hands at -$2.91 or -2.58% during last session, the market valuation stood at $136.94B. GILD’s last price was a discount, traded about -8.97% off its 52-week high of $119.96. The share price had its 52-week low at $62.69, which suggests the last value was 43.06% up since then.
Analysts gave the Gilead Sciences, Inc (GILD) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.87. If we narrow down to specifics, the data shows that 0 out of 17 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 6 recommended GILD as a Hold, 11 felt it is a Buy and 0 rated the stock as Underweight. Gilead Sciences, Inc’s EPS for the current quarter is expected to be 1.95.
Gilead Sciences, Inc (NASDAQ:GILD) trade information
Instantly GILD was in red as seen at the end of in last trading. With action 0.70%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 19.18%, with the 5-day performance at 0.70% in the green. However, in the 30-day time frame, Gilead Sciences, Inc (NASDAQ:GILD) is 13.60% up.
The consensus price target for the stock as assigned by Wall Street analysts is 126, meaning bulls need an upside of 12.63% from its current market value. According to analyst projections, GILD’s forecast low is 83 with 132 as the target high. To hit the forecast high, the stock’s price needs a -19.9% plunge from its current level, while the stock would need to tank 24.61% for it to hit the projected low.
Gilead Sciences, Inc (GILD) estimates and forecasts
Year-over-year growth is forecast to reach -0.34% down from the last financial year.
Consensus estimates given by 19 financial analysts project the company’s revenue in the current quarter to hit an average of 6.96B. 18 analysts are of the opinion that Gilead Sciences, Inc’s revenue for the current quarter will be 7.39B. The company’s revenue for the corresponding quarters a year ago was 6.95B and 7.54B respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.03%. The estimates for the next quarter sales put growth at -2.02%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -38.13%. The 2025 estimates are for Gilead Sciences, Inc earnings to increase by 72.26%, but the outlook for the next 5-year period is at 25.82% per year.
GILD Dividends
Gilead Sciences, Inc is expected to release its next quarterly earnings report in July. The 2.82% annual yield figure for the share gives it an annual dividend of 3.10. It is important to note, however, that the 2.82% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision.
Gilead Sciences, Inc (NASDAQ:GILD)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.2431% or 115.26 million shares worth $7.91 billion as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund. With 39.37 shares estimated at $4.33 billion under it, the former controlled 3.16% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard 500 Index Fund held about 2.78% of the shares, roughly 34.63 shares worth around $3.81 billion.
